NEW YORK 鈥� Nearly 900 million adults globally live with obesity鈥攁 condition linked to at least 20 diseases and projected to cost the global economy $2.76 trillion in lost GDP by 2050. GLP-1 medications have emerged as a breakthrough treatment, with prescriptions growing 38% annually between 2022 and 2024 and sales expected to reach $100 billion by 2030.
As these treatments rise to the forefront of public attention, 鈥渟ociety has ,鈥� write McKinsey鈥檚 and . 鈥淚t can react to obesity by emphasizing medical treatment and weight management drugs, or it can also pursue a broader vision that prioritizes prevention, societal shifts, and metabolic health for all.鈥�
Explore how GLP-1s are transforming obesity care, influencing the aesthetics sector, and shaping the future of health.
